Ignite Creation Date:
2025-12-25 @ 12:41 AM
Ignite Modification Date:
2025-12-25 @ 10:52 PM
Study NCT ID:
NCT04549467
Status:
COMPLETED
Last Update Posted:
2024-02-21
First Post:
2020-09-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000163', 'term': 'Acquired Immunodeficiency Syndrome'}], 'ancestors': [{'id': 'D015658', 'term': 'HIV Infections'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012897', 'term': 'Slow Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D019259', 'term': 'Lamivudine'}, {'id': 'C562325', 'term': 'dolutegravir'}, {'id': 'D000068679', 'term': 'Emtricitabine'}, {'id': 'D000068698', 'term': 'Tenofovir'}, {'id': 'D000069480', 'term': 'Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination'}], 'ancestors': [{'id': 'D016047', 'term': 'Zalcitabine'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D015224', 'term': 'Dideoxynucleosides'}, {'id': 'D063065', 'term': 'Organophosphonates'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000225', 'term': 'Adenine'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D004338', 'term': 'Drug Combinations'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 244}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-11-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-02', 'completionDateStruct': {'date': '2023-09-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-19', 'studyFirstSubmitDate': '2020-09-09', 'studyFirstSubmitQcDate': '2020-09-14', 'lastUpdatePostDateStruct': {'date': '2024-02-21', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-09-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Virologic Efficacy', 'timeFrame': '48 weeks', 'description': 'To demonstrate the non-inferior antiviral activity (VL \\< 50 c/ml) of 2DR DTG+3TC versus 3DR TDF/FTC + DTG over 48 weeks in HIV-1 naïve adult patients without baseline genotypic resistance testing available. Endpoint: Proportion of subjects with plasma HIV-1 RNA \\<50 copies/mL (c/mL) at Week 48 using the FDA Snapshot algorithm \\[Missing, Switch or Discontinuation = Failure (MSD=F)\\] for the intent-to-treat exposed (ITT-E) population.'}], 'secondaryOutcomes': [{'measure': 'Genetic barrier', 'timeFrame': '48 weeks', 'description': 'To assess the selection / emergence of viral resistance in subjects meeting confirmed virologic withdrawal (CVW) criteria. Endpoint: incidence of treatment-emergent genotypic resistance to DTG and 3TC or TDF/FTC in subjects meeting CVW criteria.'}, {'measure': 'Efficacy in presence of any major resistanceassociated mutation al baseline', 'timeFrame': '48 weeks', 'description': 'To evaluate the antiviral activity of DTG + 3TC compared to DTG + TDF/FTC over time in patients with pre-existing viral resistance based on the presence of any major resistanceassociated mutation (IAS-USA 2019). Endpoint: Proportion of subjects with plasma HIV-1 RNA \\<50 copies/mL (c/mL) at Week 48 using the FDA Snapshot algorithm and The proportion of participants with HIV-1 RNA \\<50 or \\<200 copies/mL using the observed algorithm (excluding participants with missing data) in patients with pre-existing viral resistance based on the presence of any major resistance-associated mutation (IAS-USA 2019).'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['hiv', 'antiretroviral treatment', 'dolutegravir', 'dual therapy'], 'conditions': ['Hiv', 'HIV-1-infection']}, 'referencesModule': {'references': [{'pmid': '39826566', 'type': 'DERIVED', 'citation': 'Cordova E, Hernandez Rendon J, Mingrone V, Martin P, Arevalo Calderon G, Seleme S, Ballivian J, Porteiro N. Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. Lancet HIV. 2025 Feb;12(2):e95-e104. doi: 10.1016/S2352-3018(24)00294-7. Epub 2025 Jan 15.'}], 'seeAlsoLinks': [{'url': 'http://fundacionideaa.com.ar/', 'label': 'Fundacion IDEAA web page'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy of DTG + 3TC versus DTG + TDF/FTC over 48 weeks in HIV-1 naive patients in a real life setting with no baseline HIV genotypic resistance testing available.', 'detailedDescription': 'This is a 48-week, Phase IV, randomized, open-label, to assess the non-inferior antiviral activity (VL \\< 50 c/ml) of 2DR DTG+3TC versus 3DR TDF/FTC + DTG over 48 weeks in HIV1 naïve adult patients without baseline GT available at Day 1 visit. Subjects will be stratified by screening HIV-1 RNA (≤100,000 c/mL or \\>100,000 c/mL) and Screening CD4+ cell count (≤ or \\>200 cells/mm3).\n\nThe study will comprise:\n\n* a 28-day Screening Phase (which may be extended to 35 days to allow receipt of all Screening assessment results).\n* an Open-label Randomized Phase (Day 1 to Week 48).\n\nApproximately 200 HIV-1 naïve adult patients will be randomized 1:1 to receive 2DR DTG+3TC versus 3DR TDF/FTC + DTG for 48 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Subject should be antiretroviral naïve (defined as \\<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV 1 infection).\n2. Age ≥ 18 years\n3. Screening plasma HIV-1 RNA ≥1000 c/mL\n4. CD4 cell count nadir: any value\n5. Effective contraception for women of childbearing potential.\n6. Informed consent form signed by patient and investigator\n\nExclusion Criteria:\n\n1. History of suicide ideation, intention or action.\n2. Evidence of HBV infection based on the results of testing at Screening\\* for HBV surface antigen (HBsAg), HBV core antibody (anti-HBc), HBV surface antibody (antiHBs or HBsAb), and HBV DNA as follows: Subjects positive for HBsAg are excluded; Subjects negative for anti-HBs and HBsAg but positive for anti-HBc and positive for HBV DNA are excluded.\n3. Anticipated need for any HCV therapy during the first 48 weeks of the study.\n4. Acute symptomatic HIV Infection.\n5. Any active Opportunistic Infection (category C, CDC 2014).\n6. Current pregnancy or breastfeeding.\n7. No effective contraception for the women of childbearing.\n8. Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening period to verify a result.\n9. ALT (Alanine Aminotransferase) ≥ 5 x upper limit of normal value (ULN) or AST (Aspartate Aminotransferase) ≥ 3 x ULN and bilirubinemia ≥ 1.5 x ULN (with 35% direct bilirubinemia).\n10. Unstable liver disease (ascitis, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices or persistent jaundice).\n11. Creatinine clearance of \\<50 mL/min/1.73 m2 (Cockroft-Gault method).\n12. History or presence of allergy to the trial drugs or their components.\n13. Severe hepatic insufficiency (Child Pugh Class C).\n14. Any available historical resistance test result.'}, 'identificationModule': {'nctId': 'NCT04549467', 'acronym': 'D2ARLING', 'briefTitle': 'Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test', 'organization': {'class': 'OTHER', 'fullName': 'Fundacion IDEAA'}, 'officialTitle': 'Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study)', 'orgStudyIdInfo': {'id': 'IDEAA 002'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Dolutegravir + lamivudine', 'description': 'Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD', 'interventionNames': ['Drug: Lamivudine 300 MG']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Dolutegravir + emtricitabine/tenofovir (FTC/TDF)', 'description': 'Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD', 'interventionNames': ['Drug: Emtricitabine / Tenofovir Disoproxil Pill']}], 'interventions': [{'name': 'Lamivudine 300 MG', 'type': 'DRUG', 'otherNames': ['3TC', 'dolutegravir'], 'description': 'Experimental arm', 'armGroupLabels': ['Dolutegravir + lamivudine']}, {'name': 'Emtricitabine / Tenofovir Disoproxil Pill', 'type': 'DRUG', 'otherNames': ['truvada', 'dolutegravir'], 'description': 'Active Comparator', 'armGroupLabels': ['Dolutegravir + emtricitabine/tenofovir (FTC/TDF)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '1405', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Fundacion IDEAA', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}], 'overallOfficials': [{'name': 'Ezequiel Cordova, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fundacion IDEAA'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fundacion IDEAA', 'class': 'OTHER'}, 'collaborators': [{'name': 'ViiV Healthcare', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}